Idenix Pharmaceuticals Inc

Type: Company
Name: Idenix Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.idenix.com/
First reported May 21 2013 - Updated May 21 2013 - 1 reports

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX) UBS Global Healthcare Services Conference Call May 21, 2013 8:00 AM ETMatthew Roden - UBSGood morning everyone. I am Matt Roden, biotech analyst here at UBS, and we are pleased to introduce our first speaker of the ... [Published Seeking Alpha - May 21 2013]
First reported May 19 2013 - Updated May 19 2013 - 1 reports
Aegerion Pharmaceuticals Inc
Aegerion Pharmaceuticals Inc

The Best- And Worst- Performing Biotech Stocks, May 10 To May 17

These are the best and worst-performing medical and biotech stocks from May 10 to May 17, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations ... [Published Forbes.com - May 19 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX) Bank of America Merrill Lynch Health Care Conference Call May 15, 2013 2:20 PM ETRon RenaudGood morning everyone. Before I begin I just like to remind folks that this presentation will include forward-looking statements ... [Published Seeking Alpha - May 16 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports
Phase II
Phase II

Idenix Pharmaceuticals reports net loss for Q1

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2013 was $30.75 million, or $0.23 loss per diluted share, compared to a net income of $11.45 million, or $0.10 per diluted share, ... [Published Individual.com - May 13 2013]
First reported May 08 2013 - Updated May 08 2013 - 1 reports
Idenix Pharmaceuticals Inc
Idenix Pharmaceuticals Inc

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences

CONTACT: Idenix Pharmaceuticals Contact:Teri Dahlman(617) 995-98 ... [Published Reuters - May 08 2013]
First reported May 08 2013 - Updated May 08 2013 - 1 reports

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences

(GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 11:20 a.m. PT at the ... [Published Morningstar.com - May 08 2013]
First reported May 03 2013 - Updated May 03 2013 - 1 reports

Idenix Pharmaceuticals reports encouraging data from hepatitis C virus trial

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, has reported detailed resistance data from in vitro studies and from a three-day monotherapy clinical trial of IDX719, the company's once-daily, potent, pan-genotypic NS5A inhibitor for the treatment ... [Published Individual.com - May 03 2013]
First reported May 03 2013 - Updated May 03 2013 - 1 reports

Idenix Pharmaceuticals Price Target Cut to $7.00 (IDIX)

Analysts at UBS AG decreased their price target on shares of Idenix Pharmaceuticals (NASDAQ: IDIX)IDIX has been the subject of a number of other recent research reports. Analysts at Barclays Capital cut their price target on shares of Idenix Pharmaceuticals ... [Published American Banking News - May 03 2013]
First reported May 02 2013 - Updated May 03 2013 - 1 reports

Gilead Sciences Inc. (NASDAQ:GILD) and Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) Added to Growing Stock Report's NASDAQ Decliners Watch List

New York, NY -- (SBWIRE) -- 05/02/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Gilead Sciences Inc. (NASDAQ:GILD) and Idenix Pharmaceuticals Inc. (NASDAQ:IDIX).Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical ... [Published SBWire - May 02 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Idenix Pharmaceuticals Price Target Lowered to $4.00 at Barclays Capital (IDIX)

Analysts at Barclays Capital decreased their price target on shares of Idenix Pharmaceuticals (NASDAQ: IDIX)A number of other firms have also recently commented on IDIX. Analysts at Bank of America downgraded shares of Idenix Pharmaceuticals to an "underperform" ... [Published American Banking News - May 01 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Idenix Pharmaceuticals Inc dips to net loss of USD30.8m in Q1 2013

4 minutes ago, 8:09am (ET) 05/01/2013 M2Biopharmaceutical company Idenix Pharmaceuticals Inc (NasdaqGS:IDIX) stated on Tuesday its net loss of USD30.8m (USD0.23 per basic and diluted share) for the first quarter ended 31 March 2013.This marks a drop in ... [Published Zecco - May 01 2013]
First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results

(GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, ... [Published Interest!ALERT - Apr 30 2013]

Quotes

"Get ValueWalk's Daily Edition By Email and Never Miss Our Top Stories"
Theravance Royalty Deal With Elan, Good For Baupost, Fidelity [Published Value Walk - May 13 2013]
...Phase II all-oral combination study of IDX719 and Janssen's simeprevir in the first half of the year," said Ron Renaud, Idenix's President and CEO. "We continue to be pleased with the profile of our lead uridine nucleotide prodrug candidate and are conducting studies to support an investigational new drug application submission in the first half of the year. Based on these timelines, we anticipate data readouts from these programs later this year and the initiation of a Phase II all-oral combination study of IDX719 and our lead uridine nucleotide by year-end 2"
Idenix Pharmaceuticals reports net loss for Q1 [Published Individual.com - May 13 2013]
...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
IDIX, YAVY, CVGI, HBIO, CYAN, OVRL Are Seasonally Ripe To Go Down In the Next Five Weeks [Published TradingCharts.com - May 10 2013]
...a potent, pan-genotypic component of future HCV combination treatment regimens," commented Douglas Mayers, M D , Chief Medical Officer of Idenix. "We look forward to evaluating IDX719 as part of all-oral combination therapies through our collaboration with Janssen, beginning with the initiation of a Phase II clinical trial of IDX719 and simeprevir in the first half of this year."
Idenix Pharmaceuticals reports encouraging data from hepatitis C virus trial [Published Individual.com - May 03 2013]

More Content

All (69) | News (31) | Reports (10) | Blogs (6) | Audio/Video (2) | Fact Sheets (1) | Press Releases (19)
sort by: Date | Relevance
Idenix Pharmaceuticals' CEO Presents at UBS Glo... [Published Seeking Alpha - May 21 2013]
The Best- And Worst- Performing Biotech Stocks,... [Published Forbes.com - May 19 2013]
Idenix Pharmaceuticals' CEO Presents at Bank of... [Published Seeking Alpha - May 16 2013]
Klarman Baupost Gets Into Citi (C) Warrants, DI... [Published Street Insider - May 15 2013]
Seth Klarman Buys BP, AIG, Elan Corp, Sells New... [Published Nasdaq - May 15 2013]
Seth Klarman's Worst Performing Stock Picks Yea... [Published Seeking Alpha - May 13 2013]
Theravance Royalty Deal With Elan, Good For Bau... [Published Value Walk - May 13 2013]
Idenix Pharmaceuticals reports net loss for Q1 [Published Individual.com - May 13 2013]
The Far-Off Four, 52-week Lows Held by Gurus [Published Nasdaq - May 11 2013]
IDIX, YAVY, CVGI, HBIO, CYAN, OVRL Are Seasonal... [Published TradingCharts.com - May 10 2013]
Idenix Pharmaceuticals to Present at Three Upco... [Published Reuters - May 08 2013]
Idenix Pharmaceuticals to Present at Three Upco... [Published Morningstar.com - May 08 2013]
Idenix Pharmaceuticals to Present at Three Upco... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Idenix Pharmaceuticals reports encouraging data... [Published Individual.com - May 03 2013]
Idenix Pharmaceuticals Price Target Cut to $7.0... [Published American Banking News - May 03 2013]
Gilead Sciences Inc. (NASDAQ:GILD) and Idenix P... [Published SBWire - May 02 2013]
Analysts’ Price Target Changes for May, 1st (AE... [Published American Banking News - May 01 2013]
Idenix Pharmaceuticals Price Target Lowered to ... [Published American Banking News - May 01 2013]
Idenix Pharmaceuticals Inc dips to net loss of ... [Published Zecco - May 01 2013]
8-K - IDENIX PHARMACEUTICALS INC (0001093649) (... [Published SEC Filings - Apr 30 2013]
Idenix Pharmaceuticals Reports First Quarter 20... [Published Interest!ALERT - Apr 30 2013]
Idenix Reports Favorable Resistance Profile for... [Published Drugs.com - Apr 27 2013]
Idenix Pharmaceuticals, Inc. Reports Favorable ... [Published BioSpace - Apr 24 2013]
Idenix Reports Favorable Resistance Profile for... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]
Idenix Announces Data Presentation at the 48th ... [Published GlobeNewswire: Advertising News - Apr 08 2013]
DFC Global Lowers Outlook and 2 Other Stocks At... [Published Wall St. Cheat Sheet - Apr 02 2013]
Idenix Pharmaceuticals' CEO Presents Idenix Pro... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 25 2013]
1 2 3
In Focus
  •  
Ron Renaud, Geoff Meacham, David Friedman, [more]
  •  
YUM! Brands Inc, JPMorgan Chase & Co, Deutsche Bank AG, [more]
  •  
Opexa Therapeutics, United States Patent And Trademark Office, FDA Food & Drug Administration, [more]
  •  
8-k, Healthcare Conference, Nucleotide, [more]
  •  
Lemtrada, Aubagio, Opsumit, [more]
  •  
Cambridge (Massachusetts, United States), Las Vegas (Nevada, United States), Boston (Massachusetts, United States), [more]
  •  
United States, Netherlands, Brazil, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
Construction, Insurance, IT, [more]
GlobeNewswire: Acquisitions News, SEC Filings, Healthcare Sector and Stocks Analysis from Seek..., [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DFC Global Lowers Outlook and 2 Other Stocks At... [Published Wall St. Cheat Sheet - Apr 02 2013]
DFC Global Corp.  ( NASDAQ:DLLR ): Closing price $13.04 Shares of DFC Global and those of a few of its peers in the alternative financial services (“payday lending”) industry slid after DFC posted worse than anticipated earnings per share guidance ...
Stocks to Watch: Research In Motion, Idenix, Ap... [Published WSJ.com: MarketBeat - Mar 25 2013]
Among the companies with shares expected to actively trade in Monday's session are Research In Motion, Idenix Pharmaceuticals and Apollo Group. ...
Stocks to Watch: Yum Brands, Idenix Pharma, Ope... [Published WSJ.com: MarketBeat - Feb 05 2013]
Among the companies with shares expected to trade actively in Tuesday's session are Yum Brands, Idenix Pharmaceuticals and Opexa Therapeutics. ...
Idenix, Janssen to jointly develop HCV combinat... [Published PBR - News - Jan 29 2013]
Idenix Pharmaceuticals and Janssen Pharmaceuticals have collaborated for the clinical development of direct-acting antiviral (DAA) hepatitis C virus (HCV) combination therapies, retaining all rights to their respective compounds. ...
4 Healthcare Stock Stories Not to be Missed [Published Wall St. Cheat Sheet - Jan 29 2013]
Sanofi-Aventis ( NYSE:SNY ): Closing price $48.92 Sanofi’s subsidiary Genzyme says that the  FDA has accepted for review its supplemental Biologics License Application file requesting approval of Lemtrada (alemtuzumab) for treating relapsing multiple ...
1 2

Audio/Video

sort by: Date | Relevance
Tuesday, Feb. 5, 2013: Three Stocks to Watch [Published WSJ.com Video - Business - Feb 05 2013]
Tuesday, Feb. 5, 2013: Three Stocks to Watch [Published WSJ.com Video - Hot Stocks - Feb 05 2013]
1

Press Releases

sort by: Date | Relevance
Idenix Pharmaceuticals to Present at Three Upco... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Idenix Reports Favorable Resistance Profile for... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Idenix Announces Data Presentation at the 48th ... [Published GlobeNewswire: Advertising News - Apr 08 2013]
Idenix Pharmaceuticals Announces Decision by th... [Published GlobeNewswire: Acquisitions News - Mar 22 2013]
FDA's New "Breakthrough" Designation Allows New... [Published Marketwire - Breaking News Releases - Mar 11 2013]
1 2 3 4
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.